New EU Scrutiny Procedure Less Widely Applicable And Less Complex Than Expected
This article was originally published in Clinica
One of the greatest hurdles in the future medtech Regulations – the highly demanding scrutiny procedures for high-risk devices and IVDs – now looks less widely applicable than industry had expected. Amanda Maxwell spoke with MedTech Europe’s John Brennan and Jesus Rueda to find out more
You may also be interested in...
In the EU, a two-step strengthening of requirements for clinical data means manufacturers and notified bodies need to act now, well ahead of the new Medical Device Regulations taking effect. Sarah Sorrel, president of device clinical research organization Medpass International, explains how and why in this guest column.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.